Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.

Autor:	Rudwaleit M; Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany MARTIN.RUDWALEIT@KLINIKUMBIELEFELD.DE., Deodhar A; Oregon Health & Science University, Portland, Oregon, USA., Bauer L; UCB Pharma, Monheim am Rhein, Germany., Gensler L; University of California, San Francisco, California, USA., Hoepken B; UCB Pharma, Monheim am Rhein, Germany., Kumke T; UCB Pharma, Monheim am Rhein, Germany., Auteri SE; UCB Pharma, Milan, Italy., Kim M; UCB Pharma, Smyrna, Georgia, USA., Maksymowych W; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Jazyk:	angličtina
Zdroj:	RMD open [RMD Open] 2024 May 09; Vol. 10 (2). Date of Electronic Publication: 2024 May 09.
DOI:	10.1136/rmdopen-2023-003884
Abstrakt:	Objective: There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or C-reactive protein (CRP) levels. This study reports clinical outcomes up to 3 years of the C-axSpAnd trial, including safety follow-up extension (SFE) from Weeks 52 to 156, stratified by patients' baseline MRI and CRP status. Methods: C-axSpAnd (NCT02552212) was a phase 3, multicentre study that evaluated certolizumab pegol (CZP) in patients with active nr-axSpA who had active sacroiliitis on MRI and/or elevated CRP. In this post hoc analysis, efficacy outcomes are reported to Week 156 of C-axSpAnd for patients stratified according to their MRI and CRP status at Week 0 (MRI+/CRP-, MRI-/CRP+ and MRI+/CRP+). Results: Across all outcome measures, including major improvement in Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) and Assessment of SpondyloArthritis international Society criteria ≥40% response (ASAS40), outcomes were generally sustained in SFE patients from Week 52 to Week 156. MRI+/CRP+ patients showed numerically higher or comparable responses relative to MRI-/CRP+ and MRI+/CRP- patients at Weeks 52 and 156; however, all three subgroups demonstrated substantial improvements from Week 0 (in CZP-randomised patients, ASDAS-MI at Week 156 [observed case]: MRI+/CRP+: 73.1%, MRI-/CRP+: 52.2%, MRI+/CRP-: 30.4%; ASAS40: MRI+/CRP+: 76.9%, MRI-/CRP+: 62.5%, MRI+/CRP-: 65.2%). Conclusions: In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI-/CRP+ and MRI+/CRP- subgroups. Competing Interests: Competing interests: MR: Personal fees from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, and UCB Pharma. AD: Speaker for Janssen, Novartis, and Pfizer; consulting fees from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma; research grants from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Moonlake, Novartis, Pfizer, and UCB Pharma. LB, BH, TK, SEA and MK: Employees and stockholders of UCB Pharma. LG: Grants from Novartis and UCB Pharma paid to institution. Consulting fees from AbbVie, Acelyrin, Fresenius Kabi, Janssen, Novartis, Pfizer and UCB Pharma. WM: Honoraria/consulting fees from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma; research grants from AbbVie, Pfizer and UCB Pharma; educational grants from AbbVie, Janssen, Novartis and Pfizer; Chief Medical Officer for CARE Arthritis. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu